PBAC's latest decision on Anastrozole: Recommended with restriction (2005). Considered for Extension of restricted benefit listing to allow PBS-subsidised treatment of hormone-dependent early breast cancer in all post-menopausal women.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
Post-menopausal women with hormone-dependent early breast cancer.